Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays

Wan-Fen Kuang a, Lu-Ping Chow b, Mei-Hua Wu a, Lih-Hwa Hwang a,*

a Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, ROC
b Graduate Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, Taipei, Taiwan, ROC

Received 10 April 2005
Available online 28 April 2005

Abstract

The 3C-like protease (3CL pro) of severe acute respiratory syndrome coronavirus (SARS-CoV) plays key roles in viral replication and is an attractive target for anti-SARS drug discovery. In this report, a fluorescence resonance energy transfer (FRET)-based method was developed to assess the proteolytic activity of SARS-CoV 3CL pro. Two internally quenched fluorogenic peptides, 1NC and 2NC, corresponding to the N-terminal and the C-terminal autocleavage sites of SARS-CoV 3CL pro, respectively, were used as substrates. SARS-CoV 3CL pro seemed to work more efficiently on 1NC than on 2NC in trans-cleavage assay. Mutational analysis demonstrated that the His41 residue, the N-terminal 7 amino acids, and the domain III of SARS-CoV 3CL pro were important for the enzymatic activity. Antibodies recognizing domain III could significantly inhibit the enzymatic activity of SARS-CoV 3CL pro. The effects of class-specific protease inhibitors on the trans-cleavage activity revealed that this enzyme worked more like a serine protease rather than the papain protease.

© 2005 Elsevier Inc. All rights reserved.

Keywords: SARS coronavirus; 3C-like protease; FRET-based proteolytic assay

Proteolytic processing of viral polyproteins is a key step in the replication cycle of many positive-stranded RNA viruses, and such processing in severe acute respiratory syndrome coronavirus (SARS-CoV) is performed by papain-like protease and 3C-like protease (3CL pro) [1]. The crystal structure of SARS-CoV 3CL pro was recently resolved by two groups [2,3], which reveal great similarity to the structure of the 3CL pro of porcine transmissible gastroenteritis virus (TGEV) and of human coronavirus (strain 229E), all of which form dimers [2,4]. Each monomer of the enzyme contains three structural domains: the first two domains form a chymotrypsin fold containing the catalytic site comprised of His41 and Cys145, and the third domain is a globular α-helical structure which is linked to domain II by a long loop [2–4] The extra helical domain III is unique for coronavirus 3CL pro because the picornavirus 3C proteases only contain the chymotrypsin fold, but have no extra domain [5–7]. The role of domain III in SARS-CoV 3CL pro is not quite clear but seems to be involved in dimer formation [3,4,8]. Due to its functional importance, SARS-CoV 3CL pro becomes an attractive target for structure-based drug designs against SARS [9–12].

To fulfill the needs of efficient and robust high-throughput screening of the anti-protease drugs, a convenient assay system for measuring the enzymatic activity is needed. In this study, we have established a fluorescence resonance energy transfer (FRET)-based method to assess the proteolytic activity of SARS-3CL pro. Two internally quenched fluorogenic (IQF) 11-mer peptides with N-terminus conjugated with an ortho-aminobenzoic acid (Abz) and C-terminus conjugated with a lysine-2,4-dinitrophenylamide (Lys-DNP) were synthesized and used as substrates. Upon cleavage of the substrate, the
Materials and methods

Construction of pET28b-3CLpro. The cDNA corresponding to SARS-CoV (strain TW1) nt 9985–10,902 coding for the 3CLpro protein was amplified by PCR from the reverse transcriptional mixture provided by Dr. P.J. Chen (Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan). The PCR product was cloned into the pET28b vector (Novagen) and the resulting plasmid, designated as pET28b-3CLpro, was verified by sequencing.

Expression and purification of the 3CLpro protein. The plasmid transformed Escherichia coli cells were grown at 37 °C until A600 reached 0.6–0.8 and then induced to express the recombinant protein with 0.5 mM isopropyl-1-thio-β-galactopyranoside (IPTG) for 3 h. The cells harvested were disrupted in buffer A (20 mM Tris–HCl, pH 8.0, 500 mM NaCl, and 5 mM imidazole) and cell lysate was applied to a nickel affinity column (Amersham Pharmacia Biotech AB,Upsalsa, Sweden). After wash, the 3CLpro protein was eluted with a 12–100% linear gradient of buffer B (20 mM Tris–HCl, pH 8.0, 500 mM NaCl, and 250 mM imidazole) in buffer A. The fractions containing 3CLpro were pooled and dialyzed against the storage buffer (20 mM Tris–HCl, pH 8.0, 50 mM NaCl, and 1 mM EDTA). The sample was concentrated and stored at −80 °C in storage buffer containing 50% glycerol.

The proteins were more than 95% pure as assessed by SDS-PAGE.

Deletion and point mutation. Using pET28b-3CLpro as a template, three mutant clones (H41A, ΔI–VII, and ΔIII–ΔI) were generated by exonuclease III-deleted 3CLpro (ΔI–VII). We also used the system to demonstrate that some protease inhibitors and monoclonal antibodies recognizing domain III had inhibitory effects on the proteolytic activity of SARS-3CLpro. The FRET-based real time assay provides an ideal platform for exploring the inhibitors against SARS-CoV 3CLpro and is a convenient system to study the kinetics of proteolytic reactions.

Results and discussion

Expression and purification of SARS-CoV 3CLpro and its mutants

To establish a FRET-based assay, the wild-type SARS-CoV 3CLpro was first expressed in E. coli and purified to nearly homogeneity (Fig. 1A). Meanwhile, three mutant proteins, the 3CLpro having the His41 substituted with an Ala (H41A), a deletion of the N-terminal 1–7 amino acid residues (ΔI–VII), and a deletion of domain III (from aa 201 to 306) (ΔIII), were expressed as well to assess the roles of the residue and the domains in the proteolytic activity of SARS-CoV 3CLpro. Due to the extra sequences derived from pET28b, the full-length SARS-CoV 3CLpro was expressed as a 39.5 kDa protein containing His6-tag at both the N-terminus and the C-terminus. However, it was realized that the C-terminal sequences of SARS-CoV 3CLpro, VTFQ, while in connection with the 11 amino acid residues of vector pET28b, AAALEHHHHHHH, could actually form a consensus cutting site for SARS-CoV 3CLpro, VTFQ↓AAA. The resulting protein would then be

![Fig. 1. Expression and purification of recombinant SARS-CoV 3CLpro and its mutants.](image-url)
37.4 kDa instead of 39.5 kDa (Fig. 1A). Thus, the results clearly suggest that the SARS-CoV 3CL\textsuperscript{pro} expressed possesses cis-cleavage activity.

On the contrary, all the other three mutant proteins apparently did not possess proteolytic activities, their sizes were the same as anticipated, i.e., 39.5 kDa (H41A), 38.7 kDa (Δ1–7), and 27.7 kDa (ΔIII). All the 3CL\textsuperscript{pro} and mutant proteins were recognized by a rabbit anti-SARS-CoV 3CL\textsuperscript{pro} antiserum (Fig. 1B). However, all but ΔIII were recognized by a mouse anti-SARS-CoV 3CL\textsuperscript{pro} monoclonal antibody (mAb 4) (Fig. 1C), suggesting that this monoclonal antibody might recognize the epitope residing in domain III.

**Enzymatic activity of SARS-CoV 3CL\textsuperscript{pro} and its mutants**

Two IQF peptides, 1NC and 2NC, were used for in vitro trans-cleavage assay. The sequences of these correspond to the N-terminal and the C-terminal autocleavage sites of SARS-CoV 3CL\textsuperscript{pro}, respectively. The enzymatic activities of SARS-CoV 3CL\textsuperscript{pro} toward 1NC and 2NC were analyzed by direct monitoring of the increase of fluorescence in real time (Fig. 2A). In parallel, the cleaved products obtained at the 3-h reaction were analyzed by reverse-phase HPLC (Fig. 2B). Both FRET-based and HPLC-based assays indicated that the wild-type SARS-CoV 3CL\textsuperscript{pro} had better cleavage efficiency on 1NC than on 2NC. According to the HPLC data, more than 90% of 1NC were cleaved by SARS-CoV 3CL\textsuperscript{pro} in 3 h, whereas only about 50% of 2NC were cleaved (Fig. 2B). Kinetic parameters were calculated based on the FRET-based assays. The $K_m$ value for 1NC was 145.69 μM, the $K_{cat}$ was 0.604 min\(^{-1}\), and the $K_{cat}/K_m$ was 4.143 mM\(^{-1}\) min\(^{-1}\). For 2NC, the $K_m$ was 252.47 μM, the $K_{cat}$ was 0.303 min\(^{-1}\), and the $K_{cat}/K_m$ was 1.20 mM\(^{-1}\) min\(^{-1}\).

On the contrary, the three mutants had extremely low proteolytic activities on both peptide substrates, as measured by FRET-based assays (Fig. 2A). The results indicate that the N-terminal 7 amino acids and the domain III are as important as the catalytic His41 residue in the proteolytic activity of SARS-CoV 3CL\textsuperscript{pro}.

![Fig. 2. Protease activity assays. (A) FRET-based method. The reaction contained 100 μM IQF substrate (1NC or 2NC) and 6 μM the wild-type SARS-CoV 3CL\textsuperscript{pro} or the mutant proteins, and carried out for 3 h as described under Materials and methods. The fluorescence was monitored in real time by a plate reader. (B) HPLC-based method. The reaction was carried out for 3 h and the cleaved products were analyzed by HPLC as described under Materials and methods. Peak 1 are the original peptide. Peaks 2 and 3 are the cleaved N-terminal and C-terminal fragments, respectively. Peak 4 are impurities in the original substrate solution.](image-url)
Inhibitory effects of protease inhibitors on SARS-CoV 3CL\textsuperscript{pro}

SARS-CoV 3CL\textsuperscript{pro} belongs to the cysteine protease family with a chymotrypsin fold, thus it is interesting to know whether it is inhibited by serine protease inhibitors or by cysteine protease inhibitors. The inhibitory effects of two serine protease inhibitors, TLCK and TPCK, and two cysteine protease inhibitors, NEM and E-64, were tested in this FRET-based assay. Data shown in Fig. 3 demonstrate that both serine protease inhibitors reduced the enzymatic activity of SARS-CoV 3CL\textsuperscript{pro} in a dose-dependent manner. However, the results for the two cysteine protease inhibitors were inconsistent: while NEM had significant inhibitory effects on SARS-CoV 3CL\textsuperscript{pro}, E-64 did not inhibit it at all. The data support the idea that SARS-CoV 3CL\textsuperscript{pro} works following a general base mechanism like the serine proteases, but not following a thiolate–imidazolium ion pair catalytic mechanism like the papain protease\cite{16}. However, NEM probably inhibits the proteolytic activity of SARS-CoV 3CL\textsuperscript{pro} via directly blocking the catalytic Cys145 residue, due to its ability to bind stoichiometrically to the sulfhydryl (SH) group of cysteine in the cysteine protease family.

Fig. 3. Effects of protease inhibitors on the activity of SARS-CoV 3CL\textsuperscript{pro}. Two serine protease inhibitors, TLCK and TPCK, and two cysteine protease inhibitors, NEM and E-64, ranging from 0 to 400 \(\mu\text{M}\) were added to the reaction mixture containing the 1NC substrate. Fluorescence was monitored continuously. The data shown are the (means ± SD) fluorescence intensity at the 3-h reaction.

Inhibition of SARS-CoV 3CL\textsuperscript{pro} activity by monoclonal antibodies that recognized domain III

Previously we have generated three monoclonal antibodies, mAb 3, mAb 4, and mAb 6, that could recognize full-length SARS-CoV 3CL\textsuperscript{pro} but not the protein lacking domain III (Fig. 1C and data not shown). We interpreted that these monoclonal antibodies probably recognized the epitopes residing in domain III. Therefore, we were interested to test whether they could inhibit the proteolytic activity of SARS-CoV 3CL\textsuperscript{pro} in the trans-cleavage assay. A rabbit anti-SARS-CoV 3CL\textsuperscript{pro} polyclonal antiserum was also tested. Data shown in Fig. 4 reveal that all three monoclonal antibodies could inhibit the enzymatic activity, whereas the polyclonal antiserum did not have the inhibitory activity. To our knowledge, this is the first report demonstrating that the enzymatic activity of SARS-CoV 3CL\textsuperscript{pro} could be inhibited by antibodies. The results further confirmed the pivotal roles of domain III in the proteolytic activity of SARS-CoV 3CL\textsuperscript{pro}.

In summary, a FRET-based method for detecting the proteolytic activity of SARS-CoV 3CL\textsuperscript{pro} was evaluated in this study. The kinetic studies showed that the N-terminal autocleavage site of SARS-CoV 3CL\textsuperscript{pro} was a better substrate than the C-terminal autocleavage site in the...
activity of SARS-CoV 3CLpro. Similar conclusion has also been reached for the 3CLpro of TGEV [4]. Previous crystal structure data have attributed this importance to the dimerization function mediated by these two domains [3,4,8,12]. However, a recent study by Chen et al. reported that the N-terminal seven amino acids of SARS-CoV 3CLpro were not required for enzyme dimerization. Instead, they proposed that the N-terminal domain may play, it is definitely important for the proteolytic activity of SARS-CoV 3CLpro, as demonstrated by our activity assay.

Our deletion data (Fig. 2) and antibody blocking data (Fig. 4) indicate that both the N-terminal 7 amino acids and the domain III are important for the enzymatic activity of SARS-CoV 3CLpro. Similar conclusion has also been reached for the 3CLpro of TGEV [4]. Previous crystal structure data have attributed this importance to the dimerization function mediated by these two domains [3,4,8,12]. However, a recent study by Chen et al. reported that the N-terminal seven amino acids of SARS-CoV 3CLpro were not required for enzyme dimerization. Instead, they proposed that the N-terminal domain may play, it is definitely important for the proteolytic activity of SARS-CoV 3CLpro, as demonstrated by our activity assay.

References

[1] V. Thiel, K.A. Ivanov, A. Putics, T. Hertzög, B. Schelle, S. Bayer, B. Weissbrich, E.J. Snijder, H. Rabenau, H.W. Doerr, A.E. Gorbalenya, J. Ziebuhr, Mechanisms and enzymes involved in SARS coronavirus genome expression, J. Gen. Virol. 84 (2003) 2305–2315.
[2] K. Anand, J. Ziebuhr, P. Wadhawan, J.R. Mesters, R. Hilgenfeld, Coronavirus main protease (3CLpro) structure: basis for design of anti-SARS drugs, Science 300 (2003) 1763–1767.
[3] H. Yang, M. Yang, Y. Ding, Y. Liu, Z. Lou, Z. Zhou, L. Sun, L. Mo, S. Ye, H. Pang, G.F. Gao, K. Anand, M. Bartlam, R. Hilgenfeld, Z. Rao, The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor, Proc. Natl. Acad. Sci. USA 100 (2003) 13190–13195.
[4] K. Anand, G.J. Palm, J.R. Mesters, S.G. Siddell, J. Ziebuhr, R. Hilgenfeld, Structure of coronavirus main protease reveals combination of a chymotrypsin fold with an extra alpha-helical domain, EMBO J. 21 (2002) 3213–3224.
[5] E.M. Bergmann, S.C. Mosimann, M.M. Chernaia, B.A. Malcolm, M.N. James, The refined crystal structure of the 3C gene product from hepatitis A virus: specific protease activity and RNA recognition, J. Virol. 71 (1997) 2436–2448.
[6] D.A. Matthews, W.W. Smith, R.A. Ferre, B. Condon, G. Budahazi, W. Sisson, J.E. Villafranca, C.A. Janson, H.E. McElroy, C.L. Gribkov, et al., Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein, Cell 77 (1994) 761–771.
[7] J. Seipelt, A. Guarne, E. Bergmann, M. James, W. Sommergruber, I. Fita, T. Skern, The structures of picornaviral proteases, Virus Res. 62 (1999) 159–168.
[8] J. Shi, Z. Wei, J. Song, Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors, J. Biol. Chem. 279 (2004) 24765–24773.
[9] K.V. Holmes, SARS coronavirus: a new challenge for prevention and therapy, J. Clin. Invest. 111 (2003) 1605–1609.
[10] J.E. Blanchard, N.H. Elowe, C. Huitema, P.D. Fortin, J.D. Cechetto, L.D. Ellis, E.D. Brown, High-throughput screening identifies inhibitors of the SARS coronavirus main protease, Chem. Biol. 11 (2004) 1445–1453.
[11] C.Y. Wu, J.T. Jan, S.H. Ma, C.J. Kuo, H.F. Juan, Y.S. Cheng, H.H. Hsu, H.C. Huang, D. Wu, A. Brik, F.S. Liang, R.S. Liu, J.M. Fang, S.T. Chen, P.H. Liang, C.H. Wong, Small molecules targeting severe acute respiratory syndrome human coronavirus, Proc. Natl. Acad. Sci. USA 101 (2004) 10012–10017.
[12] U. Bacha, J. Barrila, A. Velazquez-Campoy, S.A. Leavitt, E. Freire, Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro, Biochemistry 43 (2004) 4906–4912.
[13] F. Jean, A. Basak, J. DiMaio, N.G. Seidah, C. Lazure, An internally quenched fluorogenic substrate of prohormone convertase 1 and furin leads to a potent prohormone convertase inhibitor, Biochem. J. 307 (Pt. 3) (1995) 689–695.
[14] W.F. Kuang, Y.C. Lin, F. Jean, Y.W. Huang, C.L. Tai, D.S. Chen, P.J. Chen, L.H. Hwang, Hepatitis C virus NS3 RNA
helicase activity is modulated by the two domains of NS3 and NS4A, Biochem. Biophys. Res. Commun. 317 (2004) 211–217.

[15] O. Makarova, E. Kamberov, B. Margolis, Generation of deletion and point mutations with one primer in a single cloning step, Biotechniques 29 (2000) 970–972.

[16] C. Huang, P. Wei, K. Fan, Y. Liu, L. Lai, 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism, Biochemistry 43 (2004) 4568–4574.

[17] K. Fan, L. Ma, X. Han, H. Liang, P. Wei, Y. Liu, L. Lai, The substrate specificity of SARS coronavirus 3C-like proteinase, Biochem. Biophys. Res. Commun. 329 (2005) 934–940.

[18] K. Fan, P. Wei, Q. Feng, S. Chen, C. Huang, L. Ma, B. Lai, J. Pei, Y. Liu, J. Chen, L. Lai, Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase, J. Biol. Chem. 279 (2004) 1637–1642.

[19] S. Chen, L. Chen, J. Tan, J. Chen, L. Du, T. Sun, J. Shen, K. Chen, H. Jiang, X. Shen, Severe acute respiratory syndrome coronavirus 3C-like protease N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations, J. Biol. Chem. 280 (2005) 164–173.